Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Disclosure
3. Outline of presentation
4. Cancers attributable to HPV infection
5. HPV types associated with cervical cancer
6. Progression of cervical HPV infections to cancer
7. Natural history of cervical HPV infection
8. Key features of HPV pathogenesis
9. Genital warts
10. Laboratory of cellular oncology, CCR, NCI
11. Developing preventive HPV vaccine challenges
12. A prophylactic vaccine
13. Formation of papillomavirus virions
14. L1 self-assembles to form virus-like particles
15. L1 VLP induction of neutralizing antibodies
16. Systemic VLP vaccination in animal models
17. Two HPV VLP vaccines are under development
18. Merck: phase III prophylactic efficacy results
19. Possible long term protection by HPV vaccine
20. Cross-protection against other HPV types
21. Preventing HPV cervical disease efficacy
22. HPV life cycle
23. How could vaccine prevent mucosal infection
24. How could vaccine prevent cutaneous infection
25. L1 VLPs are unlikely to be directly therapeutic
26. Will the vaccines influence prevalent infection?
27. Outstanding medical issues
28. Regulatory status of HPV VLP vaccines
29. Gardasil phase III adolescent study
30. Percentage of sexually active teenagers in USA
31. Disease progression by HPV status at entry
32. We can't give up screening
33. Cervical cancer prevention by Pap screening
34. HPV-based cervical cancer prevention strategy
35. HPV vaccination in developing nations
36. Limitations of current VLP vaccines
37. Potential reduction in cervical cancer
38. Papillomaviruses neutralized by BPV1 L2
39. Vaccination with L1-Salmonella live vaccine
40. Summary and conclusions

Topics Covered

• Cervical cancer is attributable to multiple HPV types; HPV16 predominates
• Cervical cancer: time line of cervical HPV infections, progression and natural history
• Key features of HPV pathogenesis
• Challenges to development of a preventive HPV vaccine
• A prophylactic vaccine
• Formation of papillomavirus virions
• Two distinct HPV VLP vaccines are under commercial development
• Partial crossprotection against incident infection by other high risk HPV types
• Overall efficacy in preventing HPV cervical disease attributable to incident infection
• HPV life cycle
• How could IM injection of a VLP vaccine prevent mucosal or cutaneous infection at the cervix?
• Outstanding medical issues
• Regulatory status of HPV VLP vaccines
• Pap smear screening without vaccination would prevent more cervical cancer deaths than HPV16/18 vaccination without pap screening
• Limitations of current VLP vaccines

Links

Series:

• Viruses and Viral Diseases

Categories:

• Immunology
• Microbiology
• Reproduction & Development

Therapeutic Areas:

• Gynaecology & Obstetrics
• Infectious Diseases
• Vaccines

Talk Citation

Lowy, D. (2007, October 1). Papillomaviruses and HPV vaccination to prevent cervical cancer and other HPV-associated diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/YOLG3023.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on September 26, 2018

Financial Disclosures

• Dr. Douglas Lowy has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.